Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes

Chen, Y-H.; Chen, SN; Ri, Lien; Cp, Shih; An, Chen; Kj, Chen; Ys, Hwang; Wang, Nan-Kai; Lee, Kihwang; Cc, Chuang; Tl, Chen; Lai, C-C; Wc, Wu

doi:10.1038/eye.2014.172

Cited by 65 publications

(38 citation statements)

References 21 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conversely, studies have reported IVB treatment leads to lower degrees of myopic refraction than laser ablation. SE values of -1.04 D and -0.98 D have been reported in 1-to 2-year-olds in some studies (10)(11)(12) . The BEAT-ROP group recently reported refractive outcomes following IVB therapy in infants with a mean age of 2.5 years.…”

Section: Discussionmentioning

confidence: 98%

“…The introduction of IVB to ROP therapy has allowed the majority of cases of APROP to be salvaged with successful anatomic outcomes (6,9,21) . In recent years, a number of studies have assessed refractive outcomes following IVB treatment and demonstrated IVB in ROP is associated with a lower rate of refractive disorders compared to laser ablation (10)(11)(12)(13) . We therefore aimed to evaluate 2-year clinical outcomes following IVB monotherapy for APROP in infants at a referral center in Turkey.…”

Section: Discussionmentioning

confidence: 99%

“…Lesser refractive errors have been demonstrated following intravitreal beva cizumab (IVB) therapy compared to laser treatment (10)(11)(12)(13) . However, there have been few studies assessing refractive and functional outcomes following IVB treatment for APROP.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity

Günay¹,

Çelik²,

Günay³

et al. 2015

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

Approved by the following research ethics committee: Zeynep Kamil Maternity and Children's Disease Training and Research Hospital. ABSTRACTPurpose: To evaluate 2-year outcomes following intravitreal bevacizumab (IVB) as monotherapy for aggressive posterior retinopathy of prematurity (APROP). Methods: Medical records of 40 infants were retrospectively reviewed. Group I included infants who had received IVB injections for APROP. Group II included infants who underwent laser treatment for APROP. Anatomic and refractive outcomes and the presence of anisometropia and strabismus were assessed at follow-up examinations. Results: Group I included 48 eyes of 25 infants (11 males) with a mean gestational age (GA) of 26.40 ± 1.82 weeks and a mean birth weight (BW) of 901.40 ± 304.60 g. Group II included 30 eyes of 15 infants (6 males) with a mean GA of 27.30 ± 1.82 weeks and a mean BW of 941.00 ± 282.48 g. GA, BW, and gender distributions were similar between groups (P=0.187, P=0.685, and P=1.000, respectively). Refractive errors were significantly less myopic in group I (0.42 ± 3.42 D) than in group II (-6.66 ± 4.96 D) at 2 years (P=0.001). Significantly higher rates of anisometropia and strabismus were observed in group II than in group I (P=0.009 and P=0.036, respectively). Conclusions:The study demonstrated that IVB monotherapy can be useful in the treatment of APROP. The decreased incidence of early unfavorable refractive and functional outcomes in the IVB group compared with the laser group showed a potential benefit for patients treated with IVB, and this needs to be better evaluated in future prospective studies.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity

Günay¹,

Çelik²,

Günay³

et al. 2015

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

show abstract

“…The mean SEQ of IVB-treated ROP eyes at the age of 2-3 years was -1.04 [18], -0.97 [19], -2.4 [27], -1.25 [30], and -0.98 [31] dpt in previous studies. The values were thus similar in these reports and indicated a milder severity of myopia with IVB treatment than with laser treatment.…”

Section: Discussionmentioning

confidence: 99%

Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy

Kuo

Sun²,

Chung³

et al. 2015

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To evaluate the refractive development of premature infants with retinopathy of prematurity (ROP) after treatment with laser photocoagulation or intravitreal injection of bevacizumab (IVB). Methods: The medical records of patients with ROP treated between 2003 and 2012 who underwent yearly follow-ups were retrospectively reviewed. Patients with residual ROP abnormalities were excluded. The cycloplegic refraction at 3 years of age, assessed using an autorefractometer, was recorded. Results: In total, 54 eyes from 54 patients were enrolled. Patients were divided into 4 groups: group 1, including 14 eyes of 14 patients treated with laser therapy; group 2, 15 eyes of 15 patients treated with IVB; group 3, 13 eyes of 13 patients with non-type 1 ROP under conservative follow-up, and group 4, 12 eyes of 12 premature patients without ROP. The mean spherical equivalent at 3 years of age was -1.71 ± 1.27 dpt in group 1, -1.53 ± 2.20 dpt in group 2, 0.63 ± 1.37 dpt in group 3, and 0.41 ± 1.95 dpt in group 4. The mean refractive error differed significantly among the 4 groups (p < 0.001). Patients in groups 1 and 2 were more prone to myopia compared with those in groups 3 and 4. Furthermore, patients with type 1 ROP treated by laser photocoagulation (group 1) and those treated by IVB (group 2) had similar refraction (p = 1). Conclusions: The results of this study suggest that treatment-demanding ROP eyes are susceptible to more severe myopia with age compared with eyes without ROP or those with spontaneously regressed ROP. In addition, the myopic status between laser and IVB treatment did not differ statistically.

show abstract

“…81 Other retrospective reports have shown similar results. [82][83][84] Furthermore, a recent Cochrane meta-analysis that reported reduced myopia and retinal detachment with anti-VEGF agents, emphasized that the quality of evidence did not allow authors to fully rule out bias. The Cochrane review concluded that due to insufficient data and an unbeknownst systemic safety profile that strong conclusions could not be made favoring routine use of anti-VEGF agents.…”

Section: Anti-vascular Endothelial Growth Factormentioning

confidence: 99%

The Role of Anti-vascular Endothelial Growth Factor Agents in the Management of Retinopathy of Prematurity

Conrady¹,

Hartnett²

2017

US Ophthalmic Review

View full text Add to dashboard Cite

show abstract

Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes

Cited by 65 publications

References 21 publications

Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity

Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity

Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy

The Role of Anti-vascular Endothelial Growth Factor Agents in the Management of Retinopathy of Prematurity

Contact Info

Product

Resources

About